NasdaqGM:IVVDBiotechs
Invivyd (IVVD): Assessing Valuation After Strong Q3 Results and FDA Progress on VYD2311
Invivyd (IVVD) has grabbed investor attention following its third-quarter 2025 earnings report, which revealed solid revenue growth and a much smaller net loss than last year. The FDA also cleared a new drug application.
See our latest analysis for Invivyd.
Invivyd’s share price has surged in recent weeks, up 233% over the last three months and boasting a 390% year-to-date gain. Upbeat financials and the FDA’s recent approval of its drug pipeline have revived confidence in the company’s...